The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health.
Nogal A, Valdes AM, Menni C. · 2021
Read The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. by Nogal A, Valdes AM, Menni C. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8007165.txt.
Introduction
Nogal and co-authors examine how short-chain fatty acids link gut microbes, diet, and cardio-metabolic health. Gut bacteria ferment resistant carbohydrates from food into these fatty acids. Fiber-rich and omega-3-rich diets raise their production. The acids help guard the gut barrier and shape glucose and fat metabolism. They also tune the immune system, inflammation, and blood pressure.
The review first ties gut microbe imbalance to diseases such as type-2 diabetes and obesity. It then sets out what acetate, propionate, and butyrate each do. Last, it weighs diets that boost fatty acid output. The aim is care that improves heart and metabolic health through the gut.
Catalog record
| CREATOR | Nogal A, Valdes AM, Menni C. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health By Ana Nogal, Ana M Valdes, Cristina Menni Published in: Gut Microbes DOI: 10.1080/19490976.2021.1897212 ABSTRACT ABSTRACT The gut microbiota plays an important role in cardio-metabolic diseases with diet being among the strongest modulators of gut microbiota composition and function. Resistant dietary carbohydrates are fermented to short-chain fatty acids (SCFAs) by the gut bacteria. Fiber and omega-3 rich diets increase SCFAs production and abundance of SCFA-producing bacteria. Likewise, SCFAs can improve gut barrier integrity, glucose, and lipid metabolism, regulate the immune system, the inflammatory response, and blood pressure. Therefore, targeting the gut microbiota with dietary strategies leading to increased SCFA production may benefit cardio-metabolic health. In this review, we provide an overview of the association between diet, SCFAs produced by the gut microbiota and cardio-metabolic diseases. We first discuss the association between the human gut microbiota and cardio-metabolic diseases, then investigate the role of SCFAs and finally explore the beneficial effects of specific dietary interventions that can improve cardio-metabolic outcomes through boosting the SCFA production. KEYWORDS: Short-chain fatty acids, gut microbiota, diet, cardio-metabolic health, omega-3, fiber INTRODUCTION Cardio-metabolic diseases (CMD) are the most common cause of morbidity and mortality worldwide, representing a major public health challenge.1; 2 Indeed, 25% of the total population is estimated to have CMD, and approximately 30% of all the deaths are caused by CMDs.3 There are many well-established genetic and environmental risk factors associated to CMD including high blood pressure, high cholesterol, smoking, diabetes, abdominal obesity, insulin resistance, glucose intolerance among others. Recent studies suggest that gut microbiota imbalance also plays an important role in the development and progression of CMDs,4–7 including type-2 diabetes (T2D), obesity, atherosclerosis, heart failure, myocardial fibrosis, and atrial fibrillation. Moreover, the gut-brain axis has been implicated in neurogenic hypertension,8 which is particularly relevant for people suffering from obstructive sleep apnea,9 and gut microbiome composition has been linked to sleep architecture in these patients.10 Given the strong link between inflammation and sleep apnea, it is likely that SCFAs/gut microbiome links relating to hypertension may also link to sleep apnea and other disorders.11 Gut microbiota can exert beneficial or detrimental effects in human health12 through the production of metabolic products and signaling molecules, which influence diverse functions in different organs.13 Among these bacteria-derived metabolites, short-chain fatty acids (SCFA) are gaining attention as a potential focus of CMD.14 SCFAs, namely acetate, propionate, and butyrate, are produced through bacterial fermentation of fibers (e.g., resistant starch, simple sugars, and polysaccharides),15 and present regulatory functions in the lipids, cholesterol and glucose metabolism, anti-inflammatory and immune response and gut barrier integrity.16 SCFAs might protect against CMD as they are able, for instance, to decrease plasma cholesterol and glucose levels and increase fatty acid oxidation.17 Likewise, the type of diet can modulate SCFA production and/or abundance of SCFA-producing bacteria. For instance, a Mediterranean diet, characterized by a high consumption of fiber-rich food, or omega-3-rich diets, has been correlated with higher levels of SCFAs and SCFA-producing bacteria.18,19 Previous reviews addressed SCFAs, CMD or, diet and their links to gut microbiome composition,20–25 however none of them has yet simultaneously covered the role of SCFAs in the interplay between diet, gut microbes, and CMD. Indeed, most of the previous reviews do not discuss in detail SCFAs23 nor their beneficial role in cardio-metabolic health,20 nor how different types of diet can increase SCFAs production to improve the health of patients suffering from CMDs.21,22,24,25 In the present review, on the contrary, we specifically focus on the association between the human gut microbiota and CMDs, the metabolic routes involved in the SCFA production, the benefits exerted by SCFAs in cardio-metabolic health, and the involved mechanisms. Finally, we discuss a number of recent clinical studies supporting the beneficial effects of specific dietary interventions that can improve cardio-metabolic outcomes through boosting SCFAs production. GUT MICROBIOTA The human intestine contains approximately 1014 microorganisms, collectively known as the gut microbiota.26 The gene repertoire present in these microbes is 100-fold higher than the number of genes present in the human genome.27 In a healthy gut microbiota, the most predominant phyla are Firmicutes and Bacteroidetes (90% of the population), followed by Actinobacteria and Verrucomicrobia,28 although inter-variability between individuals exists. Gut microbiota diversity, richness, and composition vary depending on multiple determinants, either endogenous such as sex, microbial interactions, and host genotype,26,29 or exogenous, such as diet, age, usage of antibiotics, exercise, smoking, and stress.30 Over the last years, advances in bioinformatics tools and next-generation sequencing have increased our knowledge on the relationship between microbiota organisms and humans,31 allowing us to discover the benefits and detriments of the gut bacteria to human health. Bacteria-derived metabolites play important functions in the intestine (e.g., digestion, energy harvest, and barrier integrity)32 and even in other organs when they enter into the systemic circulation (e.g., glucose circulation in the pancreas, lipid metabolism in the liver, and cognitive functions in the brain).13 When there is an intestinal microbial ecosystem balance (eubiosis), the gut microbiota plays important immunological, homeostatic, and metabolic functions that maintain the human host health.33 On the other hand, the imbalance of the gut microbiota, known as dysbiosis, and reduction of bacterial diversity can lead to a variety of metabolic abnormalities, such as inflammation and oxidative stress, impacting negatively on the host pathophysiologic and physiology conditions.34 GUT MICROBIOTA IN CARDIO-METABOLIC HEALTH The role of the gut microbiota has recently been implicated in the development and progression of CMD.35,36 Many studies have shown alterations in the composition and function of the gut bacteria in patients suffering from CMDs. Animal and human obesity has been associated with an increased Firmicutes/Bacteroidetes ratio.37 Moreover, gut dysbiosis can reduce the gut barrier integrity, affecting glucose sensibility and absorption, leading to insulin resistance and T2D.38 Another example is the lipopolysaccharides (LPS) present in the Gram-negative bacteria cell wall, which can trigger the immune system response and potentiate cardiovascular diseases (CVD) pathogenesis.39,40 Our body can functionally interact with bacteria metabolic products,16 and cardio-metabolic health (CMH) is associated with these metabolic products. Trimethylamine (TMA),41–45 bile acids46–49 are examples of metabolic products that have been negatively associated with CMD, whereas SCFAs,14 anthocyanins50 and indoleproprionic acid51 might influence positively the host health. TMA is metabolized from choline-containing compounds (e.g., choline, betaine, and L-carnitine) present in human diet by the gut microbiota.52 Then, TMA enters to the portal circulation, where is oxidized by liver enzymes to produce trimethylamine‑N‑oxide (TMAO).53 TMAO pathway has been associated with atherosclerosis and thrombosis promotion in mouse,41–43 and with CMD in humans such as obesity, chronic kidney disease, and T2D.44,45,54 Detailed therapeutic potential and clinical prognostic of TMAO in CMD can be found in several reviews.55–57 Gut microbiota is responsible for the generation of unconjugated free bile acids and secondary bile acids through deconjugation and dihydroxylation reactions.58 Bile acids can act as signaling molecules involved in inflammation, host metabolism, and energy expenditure, and thus, they might play a role in CMD.46–49 The role of bile acids in metabolic disorders and CVD has been reviewed by.59,60 Anthocyanins are glycosyl-anthocyanidins present in plant vacuoles. Gut bacteria can degrade anthocyanins, generating protocatechuic acid and free anthocyanidins.61 Protocatechuic acid can influence positively atherosclerosis and CVD, thanks to its anti-inflammatory and